文献速递儿科与产科急症重症综合管理与镇静镇痛

早产儿重度血小板减少症个体化预测血小板输注结局

Individualized Prediction of Platelet Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia.
PubMed 文献 · JAMA · 2025-01-01
一句话结论在胎龄<34周的重度血小板减少早产儿中,动态预测模型可个体化估计预防性血小板输注与否的3天主要出血或死亡风险,模型在验证队列中表现良好,但支持个体化决策的价值尚待未来研究评估。

该研究开发并验证了一个动态预测模型,用于估计重度血小板减少(血小板计数<50×10^9/L)早产儿在接受或不接受预防性血小板输注时3天内主要出血或死亡的风险。模型在荷兰、瑞典和德国的14个新生儿重症监护病房(2017-2021年,n=1042)中开发,并在荷兰7个新生儿重症监护病房(2010-2014年,n=637)中验证。验证队列中,预防策略的时间依赖AUC为0.69(95%CI 0.60-0.76),无预防策略为0.85(95%CI 0.76-0.92),校准良好。预测风险因患儿临床特征不同而差异显著,提示预防性输注的获益与危害存在个体差异,但模型支持个体化决策的价值尚待未来研究评估。

要点

  • 在胎龄<34周的重度血小板减少早产儿中,预防性血小板输注的获益与危害存在个体差异,取决于预测时的临床特征。
  • 动态预测模型每2小时重新评估3天内主要出血或死亡风险,对比6小时内输注血小板与3天不输注两种策略。
  • 验证队列中模型区分度:预防策略时间依赖AUC 0.69(95%CI 0.60-0.76),无预防策略AUC 0.85(95%CI 0.76-0.92),校准良好。
  • 预测因子包括胎龄、日龄、小于胎龄儿、坏死性小肠结肠炎、脓毒症、机械通气、血管活性药物、血小板计数和既往血小板输注。
  • 作者认为该模型支持个体化决策的价值尚待未来研究评估。

适用人群与场景

  • 胎龄<34周的重度血小板减少(血小板计数<50×10^9/L)早产儿,收治于新生儿重症监护病房。

诊断标准与关键阈值

  • 重度血小板减少定义为血小板计数<50×10^9/L。

研究设计与关键结果

  • 研究类型为动态预测模型开发与外部验证研究;开发队列为国际多中心队列(2017-2021年,荷兰、瑞典、德国14个新生儿重症监护病房,n=1042),验证队列为荷兰全国多中心队列(2010-2014年,7个新生儿重症监护病房,n=637)。
  • 开发队列和验证队列的中位胎龄均为28周,中位出生体重均为900 g;男性分别为613例(59%)和370例(58%)。
  • 主要出血或死亡在开发队列中发生235例(23%),在验证队列中发生135例(21%)。
  • 验证队列中,预防策略的时间依赖AUC为0.69(95%CI 0.60-0.76),无预防策略为0.85(95%CI 0.76-0.92),校准图显示校准良好。
  • 两种策略下的估计风险因预测时患儿临床状况不同而差异显著。

证据类型、等级与局限

  • 证据类型:国际多中心队列研究(模型开发)及全国多中心队列研究(外部验证)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该动态预测模型在验证队列中表现良好,其支持个体化决策的价值尚待未来研究评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Preterm infants with severe thrombocytopenia (platelet count <50 × 109/L) frequently receive platelet transfusions. However, it is unclear in what cases prophylactic transfusion truly reduces bleeding risk or whether it does more harm than good.

OBJECTIVE: To develop and validate a dynamic prediction model for major bleeding or mortality if prophylactic platelet transfusion were or were not to be given to infants with severe thrombocytopenia.

DESIGN, SETTING, AND PARTICIPANTS: The dynamic prediction model was developed in an international multicenter cohort (2017-2021) comprising 14 neonatal intensive care units in the Netherlands, Sweden, and Germany. Model evaluation was performed in a national multicenter cohort (2010-2014) including 7 Dutch neonatal intensive care units. The study population consisted of infants with severe thrombocytopenia less than 34 weeks' gestation.

EXPOSURE: Two transfusion strategies were contrasted at each prediction point: receiving a platelet transfusion within 6 hours (prophylaxis) vs no platelet transfusion for 3 days (no prophylaxis).

MAIN OUTCOMES AND MEASURES: The primary outcome was the 3-day risk of major bleeding or mortality, reestimated every 2 hours during the first week after severe thrombocytopenia onset. Predictors included gestational and postnatal age, small-for-gestational-age infant, necrotizing enterocolitis, sepsis, mechanical ventilation, vasoactive agents, platelet count, and prior platelet transfusion(s). Landmarking combined with the clone-censor-weight approach enabled dynamic prediction under the 2 transfusion strategies, accounting for time-varying confounding. Model performance was evaluated in the external validation cohort.

RESULTS: In both the development (n = 1042) and validation (n = 637) cohorts, the median gestational age was 28 weeks and median birth weight was 900 g; there were 613 (59%) and 370 (58%) males, respectively. Major bleeding or death occurred in 235 infants (23%) in the development cohort and 135 (21%) in the validation cohort. In the validation cohort, the time-dependent area under the receiver operating characteristic curve was 0.69 (95% CI, 0.60-0.76) for the prophylaxis strategy and 0.85 (95% CI, 0.76-0.92) for the no prophylaxis strategy, with calibration plots showing good calibration. Estimated risks under both strategies varied considerably depending on the infant's clinical condition at the time of prediction.

CONCLUSIONS AND RELEVANCE: Among preterm infants with severe thrombocytopenia, this modeling study found substantial variation among individuals in predicted benefits and harms of prophylactic platelet transfusion based on their current clinical characteristics. The dynamic prediction model performed well in a validation cohort, and its value to support individualized decisions warrants evaluation in future studies.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. van der Staaij H, Prosepe I, Caram-Deelder C, et al. Individualized Prediction of Platelet Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia. JAMA. 2025. PMID: 40952748. doi:10.1001/jama.2025.14194

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。